Stroke - international conference 2006.
Michel
Patrik
P
Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, 1011 Lausanne, Switzerland. patrik.michel@chuv.ch
Bogousslavsky
Julien
J
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors / Q000235:genetics; D058927:5-Lipoxygenase-Activating Proteins; D001557:Benzenesulfonates / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D002986:Clinical Trials as Topic; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D006801:Humans; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D009589:Nitrogen Oxides / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy* / Q000235:genetics
D058927:5-Lipoxygenase-Activating Proteins; C548592:ALOX5AP protein, human; D001557:Benzenesulfonates; D002317:Cardiovascular Agents; D002352:Carrier Proteins; D008565:Membrane Proteins; D009589:Nitrogen Oxides; C120851:disufenton sodium; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4